Cevostamab (RG6160) is a FcRH5 × CD3 TCE which binds to a membrane-proximal epitope of FcRH5, leading to efficient synapse formation and MM cell killing [77]. This evidence concerns the gene FCRL5 and Miyoshi myopathy.